الصفحة 32
الصفحة 32
Catastrophe modeling : A new approach to managing risk
Catastrophe Modeling: A New Approach to Managing Risk is the first book that systematically analyzes how catastrophe models can be used for assessing and managing risks of extreme events. It focuses on natural disaster risk, but also discusses the management of terrorism risk. A unique feature of this book is the involvement of three leading catastrophe modeling firms, AIR Worldwide, EQECAT, and Risk Management Solutions, who examine the role of catastrophe modeling in rate setting, portfolio management and risk financing. Given the uncertainties associated with terrorism the book points out the opportunities for utilizing catastrophe models to set insurance rates and to examine public-private partnerships for providing financial assistance in the event of a terrorist attack. This book is strongly recommended for individuals who must make decisions regarding the management of impacts of catastrophe risks including those in both the public and private sector.
Career options in the pharmaceutical and biomedical industry : An insider’s guide
Divided into five parts: Part 1 provides an academic perspective that focuses on the specific preparation required in the final years of study to embark on a successful career in the pharmaceutical and biomedical industries. In Part 2, industry experts discuss employment possibilities all along the drug or product life cycle,from discovery research and development to commercialisation. Part 3 follows, highlighting opportunities in support functions such as regulatory affairs or quality assurance. Part 4 focuses on additional opportunities in the wider biomedical sector, while Part 5 contains practical tips and training opportunities for entering the pharmaceutical and biomedical industries. In the epilogue, the authors reflect on this fascinating field and its career prospects.
Care in Healthcare : Reflections on Theory and Practice
This book examines the concept of care and care practices in healthcare from the interdisciplinary perspectives of continental philosophy, care ethics, the social sciences, and anthropology. Areas addressed include dementia care, midwifery, diabetes care, psychiatry, and reproductive medicine. Special attention is paid to ambivalences and tensions within both the concept of care and care practices. Contributions in the first section of the book explore phenomenological and hermeneutic approaches to care and reveal historical precursors to care ethics. Empirical case studies and reflections on care in institutionalised and standardised settings form the second section of the book.
Cardiovascular Regeneration Therapies Using Tissue Engineering Approaches
The cardiovascular system transports oxygen and nutrients to all parts of the body; therefore, any impediment to this system through, for example, a circulatory disorder, represents a serious threat to organs, tissues, and cells. Obstructive diseases of vessels with a diameter of more than 1 mm can be treated by conventional surgical and interventional approaches; however, blockages in small vessels with a diameter of less than 1 mm cannot be treated by conventional methods. As a consequence, therapeutic ang- genesis and vasculogenesis for the treatment of ischemic diseases have been widely studied in the last decade. These methods may contribute to the re pair of intractable cardiovascular diseases with a main vascular involvement in the body's smallest vessels. In this book, Hikaru Matsuda and I have tried to summarize recent Japanese developments in the field of cardiovascular regeneration therapies using tissue engineering.
Cardiovascular English
The multiplicity of cardiological tests and therapeutical procedures demands a sound knowledge of cardiological English and can be extremely demanding for non-native English speaking cardiologists, cardiology residents, nurses, and medical students.
Cardiac drug therapy
Cardiac Drug Therapy, 7th ed., addresses the pharmacology and therapeutic application of drugs used to treat heart diseases and hypertension. Additions and updates to the sixth edition include six new chapters on current controversies in cardiac drug therapy such as the beta blocker issue many cardiologists are presently grappling with. The book provides practical advice on how to manage cardiac diseases and addresses the choice of one particular cardiac agent vs. another. In addition to providing core knowledge in cardiovascular therapeutics, the text assists in resolving some of the issues surrounding cardiac drugs. Cardiac Drug Therapy provides practical information including properties, dosage, side effects, potential salutary benefits, and drawbacks on virtually all commercially available cardiac drugs.
Carbon monoxide in drug discovery, basics, pharmacology, and therapeutic potential
Carbon monoxide, one of the smallest organic natural molecules, is widely known for its toxicity. Formation of CO via incomplete combustion is a major contributing factor to accidental or intentional CO poisoning, leading to severe health consequences or death. In addition, CO is a by-product of tobacco smoking, and has been associated with some of the harmful effects of smoking. However, less known and probably far more important is the recognition of the essential physiological roles of CO as a signaling molecule in mammals. Against over more than a century of negative connotation, the last few decades have proven that CO possesses a multitude of physiological roles and therapeutic functions including regulation of the immune response, cellular proliferation, and control of cell survival. This concept is supported by the discovery that CO is produced by all cells and more so under conditions of stress. This book comprehensively summarizes key aspects of CO's endogenous roles, therapeutic functions, and challenges that we face in its development as a therapeutic agent. We hope this preface will provide a thread for reading this book and a birds-eye view of the landscape for understanding this field, and more importantly lay out the challenges ahead in understanding the detailed mechanisms of action of CO and in its development as a therapeutic agent.
Carbohydrate-based therapeutics
Explores new frontiers in carbohydrate-based therapeutic applications, utilizing a unique approach by providing a detailed background of diseases coupled with subsequent carbohydrate-based therapies. The link between chemistry and design of novel carbohydrate-based medicines is highlighted and a broad overview of all the potential applications of carbohydrates is given. Emphasis is laid on concepts used for carbohydrate drug design, structure– activity relationship, and impact on health and diseases. The text also discusses newer topics like nanoparticles, material science, and tissue generation.
Cannabinoids as Therapeutics
this volume concentrates on the diseases, the physiological effects and therapeutic use of cannabinoids. The volume editor Prof. Mechoulam was the first who isolated the prime active constituent (THC, Tetrahydrocannabiol) of marijuana. He published extensively on the pharmacological activities of cannabinoids. The volume is of interest to researchers and clinicians from pharmacology, neuroscience, and medicinal research
Cannabinoids and sleep : Molecular, functional and clinical aspects
Offers a comprehensive overview on cannabinoids and their effects on sleep Provides novel research findings on the therapeutic potential of cannabinoids Discusses the effect of cannabinoids in several neurological disorders
Cancerimmunotherapies : Solid tumors and hematologic malignancies
Presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations.
Cancer vaccination and challenges Vol.1 : strategies for therapeutic cancer vaccine development
Deals with different strategies of cancer vaccine development, focusing on techniques for the development of therapeutic cancer vaccines and the roles of tumor antigens, proteins/peptides, microbial genes, and stem cells for the development of vaccines for cancer management.
Cancer immunotherapy
Defining Cancer as a disease in which some of the body's cells grow uncontrollably and spread to other parts of the body, making it an enormous medical and economic burden accounting for 9.6 million deaths in 2018. Cancer treatments were being introduced for a long time. The development of specific therapies to treat cancer really depends on the continued discovery of the molecular changes that lead to the malignant progression of human cancers. More and more drugs are being developed to block cancer pathways that lead to impaired growth and survival of cancer cells. In this dissertation, the concept of cellular and immunotherapy of cancer will be discussed briefly, taking into considerations the mechanisms of action, the advantages, challenges and drawbacks of the different types of monoclonal antibodies and CAR T-Cell therapy.
Cancer du testicule = Testicular cancer
Testicular cancer has benefited from important therapeutic advances radically transforming its prognosis. Recent protocols have led to the development of treatments that maintain therapeutic efficacy while favoring quality of life and minimizing the sequelae (such as fertility disorders) in these often young men. This book discusses the various technical advances both in the field of diagnosis - with the contribution of modern imaging and anatomopathology - and therapy. The place of chemotherapy as well as that of surgery are largely detailed, thus placing the urologist at the heart of the multidisciplinary team taking care of these patients. Quality of life is also discussed by taking into account the impact of the treatment of these tumors on the fertility of these young patients.
Cancer du sujet âgé = Cancer in the elderly
Etablir un diagnostic précoce, définir une stratégie adaptée et offrir une meilleure qualité de vie chez le sujet âgé atteint de cancer constituent les défis de l’Oncologie de ce début de siècle. Cet ouvrage a pour objectif de proposer aux médecins et aux étudiants un condensé des différents aspects de l’oncologie sur le sujet âgé. Dans une première partie, les aspects épidémiologiques et biologiques ainsi que l’évaluation gériatrique multiparamétrique sont abordés. Les particularités de l’application de la chimiothérapie, de la radiothérapie et de la chirurgie au sujet âgé sont passées en revue. Dans une troisième partie, la stratégie thérapeutique multidisciplinaire est ensuite détaillée par site.
Cancer du sein avancé : 29es Journées de la Société Française de Sénologie et Pathologie Mammaire (SFSPM) Avignon, 14–16 novembre 2007 = Advanced breast cancer : 29th Days of the French Society of Senology and Breast Pathology (SFSPM) Avignon, November 14–16, 2007
These days are an opportunity to remind and persuade those less convinced that the treatment of this very particular phase of the disease is not limited to a score played by a few speakers or even by medical oncologists alone; but on the contrary, we must bring into play a truly philharmonic polyphonic ensemble, united around the patient and comprising all the players in multidisciplinary care: general practitioner, surgeon, radiotherapist, imaging specialist, gynecologist, general practitioner, psychologist, algologist, supportive care workers ...
Cancer drug safety and public health policy : A changing landscape
Description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. Opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention – these fines are playing an important role in changing the landscape for pharmaceutical safety.
Cancer drug resistance
In Cancer Drug Resistance, leading scientists from the best academic institutions and industrial laboratories summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to a wide variety of anticancer therapeutics, as well as suggest new approaches to the biology of drug resistance that may afford new therapeutic opportunities.
Cancer
The last decade has seen a dramatic shift in anticancer drug research towards agents that aim to target selectively key regulatory and signaling processes known to drive tumorigenesis. A number of these newer agents have now been introduced into clinical practice. This volume reviews advances in cancer chemotherapy research over the last 10 years and will be of interest to scientists engaged in drug research in the pharmaceutical industry, biotechnology and startup companies, academia and government institutions. Chapters written by leading experts in their field reflect a range of current medicinal chemistry approaches to small molecule drugs, including anti-hormonal therapy, growth factor inhibition, survival signaling, cell cycle inhibition, anti-angiogenics and anti-nvasives. Each chapter aims to cover the drug target and biological rationale, chemotypes, clinical status and future prospects in this rapidly developing area of drug research.
CADD and informatics in drug discovery
Updates knowledge on recent advances in computational and bioinformatics tools/techniques and their practical applications in modern drug design and discovery programme. Also it encompasses fundamental principles, advanced methodologies and applications of various CADD approaches including several cutting-edge areas / presenting recent developments covering ongoing trends in the field of computer-aided drug discovery. Having contributions by a global team of experts, the book is expected to be an ideal resource for drug discovery scientists, medicinal chemists, pharmacologists, toxicologists, phytochemists, biochemists, biologists, RandD personnel, researchers, students, teachers and those working in the field of drug discovery. It will fill the knowledge gaps that exist in the current CADD approaches and methodologies/ protocols being widely used in both academic and research practices. Further, a special focus on current status of various computational drug design approaches (SBDD, LBDD, De-novo drug design, Pharmacophore-based search), bioinformatics tools and databases, computational screening and modeling of phytochemicals/natural products, artificial intelligence and machine learning, and network pharmacology and system biology would certainly guide researchers, students or readers to conduct their research in the emerging area(s) of interest. It is also expected to be highly beneficial to different stakeholders working in the pharmaceutical and biotechnology industries (RandD), the academic as well as research sectors. .
